T
Thomas Powles
Researcher at Queen Mary University of London
Publications - 804
Citations - 57482
Thomas Powles is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 82, co-authored 655 publications receiving 39271 citations. Previous affiliations of Thomas Powles include Charing Cross Hospital & University of London.
Papers
More filters
Journal ArticleDOI
A phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO).
Thomas Powles,James Larkin,Poulam M. Patel,Begoña Perez-Valderrama,Alejo Rodriguez-Vida,Hilary Glen,Fiona C Thistlethwaite,Christy Ralph,Gopalakrishnan Srinivasan,M.J. Méndez-Vidal,Wing-Kin Liu,Aaron Prendergast,Laura Vosper,Kelly Mousa,Cristina Suárez +14 more
TL;DR: The combination of savolitinib and durvalumab appears safe and associated with clinical activity in PRC and will take forward to phase II of this single arm phase I/II trial.
Journal ArticleDOI
IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC).
Maha Hussain,Thomas Powles,Peter Albers,Daniel Castellano,Siamak Daneshmand,Juergen E. Gschwend,Hiroyuki Nishiyama,Stéphane Oudard,Darren Tayama,Nicole N. Davarpanah,Viraj Degaonkar,Yi Shi,Sanjeev Mariathasan,Petros Grivas,Peter H. O'Donnell,Jonathan E. Rosenberg,Daniel M. Geynisman,Jean H. Hoffman-Censits,Daniel P. Petrylak,Joaquim Bellmunt +19 more
TL;DR: This data indicates that conventional surgery ± cisplatin-based neoadjuvant chemo (NAC) is the mainstay treatment for MIUC, with no conclusive level 1 evidence for adjuvant Chemo (AC).
Journal ArticleDOI
A synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump BCRP.
Jackie Perry,Essam Ghazaly,Christiana Kitromilidou,Eva H. McGrowder,Simon P. Joel,Thomas Powles +5 more
TL;DR: It is shown that lapatinib has a direct inhibitory effect on BCRP accounting for the synergistic findings, and the synergy is cell line dependent and related to the activity of specific efflux pumps.
Journal ArticleDOI
A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer
Thomas Powles,Irfan Kayani,K. Sharpe,Louise Lim,J. Peters,Grant D. Stewart,Daniel M. Berney,Anju Sahdev,Simon Chowdhury,Ekaterini Boleti,Jonathan Shamash,Andrew R. Reynolds,Robert Jones,Christian U. Blank,John B. A. G. Haanen,Axel Bex +15 more
TL;DR: Progression during planned VEGF TKI treatment interruptions is frequent and associated with a poor prognosis, and treatment cessation should be pursued with caution.
Journal ArticleDOI
Phase 3 KEYNOTE-361 trial: Pembrolizumab (pembro) with or without chemotherapy versus chemotherapy alone in advanced urothelial cancer.
Thomas Powles,Juergen E. Gschwend,Yohann Loriot,Joaquim Bellmunt,Lajos Géczi,Christof Vulsteke,Mahmoud Abdelsalam,Rustem Gafanov,Woo Kyun Bae,János Révész,Yoshiaki Yamamoto,Urbano Anido,Wen-Pin Su,Mark D. Fleming,Maurice Markus,Dai Feng,Christian Heinrich Poehlein,Ajjai Alva +17 more
TL;DR: A small number of patients with advanced bladder cancer attain long-term survival with standard first-line cisplatin-based chemotherapy with programmed death 1 (PD-1)/PD-L1 inhibiting chemotherapy, and this data indicates that a second line therapy is needed.